Fenwick represented OrsoBio, a
clinical-stage biopharmaceutical company developing treatments for severe
metabolic disorders, in its $60 million Series A financing. The round was
co-led by Longitude Capital and Enavate Sciences, with participation from
Samsara BioCapital, NuevaBio and Eli Lilly and Company.
OrsoBio will use the funds to support the advancement of
OrsoBio’s obesity-focused portfolio. More information can be obtained from the company’s announcement.
The Fenwick transaction team was led by corporate partner
Bill Bromfield and included associates Leeza Soulina and Jing Liu.